<DOC>
	<DOCNO>NCT00717522</DOCNO>
	<brief_summary>The purpose study determine safety efficacy single agent CC-4047 ( pomalidomide ) patient advance soft tissue sarcoma relapse refractory prior anticancer therapy .</brief_summary>
	<brief_title>Efficacy Safety Study CC-4047 ( Pomalidomide ) Treat Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must &gt; 18 year age Must histologically confirm soft tissue sarcoma Must locally recurrent unresectable , metastatic soft tissue sarcoma , fail relapse minimum one maximum 3 prior systemic anticancer therapy regimens Must measurable evaluable disease determine per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion Must document disease progression ( PD ) determine per RECIST criterion within 3 month prior study enrollment Must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Pregnant lactating female Prior therapy thalidomide lenalidomide Prior use experimental/investigational drug therapy &lt; 3 month prior treatment initiation Prior chemotherapy , biologic immunotherapy &lt; 3 week prior treatment initiation Prior radiotherapy &lt; 3 week prior treatment initiation Prior major surgery &lt; 3 week prior treatment initiation Absolute neutrophil count ( ANC ) &lt; 1.5 x 109 cells/L Platelet count &lt; 100 x 109cells/L Aspartate aminotransferase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine aminotransferase/serum glutamic pyruvate transaminase ( ALT/SGPT ) &gt; 3.0 x upper limit normal ( ULN ) &gt; 5.0 x ULN presence demonstrable liver metastasis Known active central nervous system ( CNS ) metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Soft Tissue Sarcoma</keyword>
	<keyword>CC-4047</keyword>
	<keyword>Pomalidomide</keyword>
</DOC>